S53P4 bioactive glass was used for treatment of chronic osteomyelitis in the lower extremity and the spine in a multicentre clinical study of 12 patients aged between 16 and 84 years. Staphylococcus aureus was found to be the most common pathogen causing the infection. The mean follow-up time was 24 months. Bioactive glass was well tolerated and no adverse effects were observed. Clinical outcome was good or excellent in 9 of 11 patients. The use of bioactive glass resulted in a fast recovery.
Bioactive glass S53P4 as bone graft substitute in treatment of osteomyelitis.
Lindfors NC, Hyvönen P, Nyyssönen M, Kirjavainen M, Kankare J, Gullichsen E, Salo